Positioning and Growth Financing of ELIOS Vision in the Glaucoma Market
Positioning and Growth Financing of ELIOS Vision in the Glaucoma Market
Outcome Capital’s expertise in delivering strategic advisory and investment banking services throughout a client’s life cycle and growth is exemplified by our partnership with ELIOS Vision, a pioneering medical technology company developing next generation of glaucoma treatment. Outcome Capital provided ELIOS Vision with strategic support and investment banking expertise since its inception in early 2019 and played a critical role in the company’s growth and success. Over the past several years, Outcome helped position ELIOS Vision as a key innovator in the $2.5 billion glaucoma treatment market, leading to the company’s recent acquisition by global eye health player Bausch + Lomb.
Read the case study:
News
A Panic Letter and the Quiet Reset of American Biotech
This article examines the quiet but profound reset underway in U.S. biotech, triggered by a rare combination of forces: delayed or reduced federal funding, large pharma cutting mid-stage partnerships, and venture capital pulling back as exits evaporate. Based on insights from Dr. Stanislav Glezer, it reveals a market splitting in two — with capital chasing late-stage and very early assets while Phase 1–2 companies are stranded in the middle. The piece also exposes how government uncertainty, shrinking NIH support, and overlooked patient-behavior realities are forcing founders to rethink their entire company lifecycle. In today’s environment, survival requires new strategies, new geographies, and a deeper understanding of human factors that no protocol can fix.
Read MoreResources
Outcome Capital Life Science Market Pulse, October 2025
Outcome Capital Life Science Market Pulse October 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
